Monitoring thiopurine metabolites in inflammatory bowel disease.

Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut (2001) 2.56

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.75

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 1.74

Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology (2015) 1.51

Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol (2008) 1.49

High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther (2012) 1.46

Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol (2007) 1.39

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol (2004) 1.33

Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev (2000) 1.32

Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32

Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis (2013) 1.31

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol (2005) 1.27

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol (2004) 1.26

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2012) 1.25

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2013) 1.18

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther (2002) 1.16

Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther (2009) 1.14

Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis (2010) 1.09

6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am (1989) 1.09

Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2009) 1.05

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther (2012) 0.99

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2008) 0.97

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther (2004) 0.90

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol (2015) 0.90

Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit (2006) 0.89

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol (2010) 0.88

Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis (2015) 0.88

Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol (2013) 0.88

Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis (2012) 0.87

Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci (2007) 0.86

The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol (2012) 0.84

Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol (2010) 0.84

Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis (2010) 0.83

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev (2014) 0.83

Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci (2000) 0.82

Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis (2011) 0.82

6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther (2005) 0.82

The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis (2013) 0.82

The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease. Ther Drug Monit (2011) 0.81

Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 0.81

Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease. J Clin Gastroenterol (2014) 0.80

Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. J Gastroenterol Hepatol (2012) 0.80

Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol (2009) 0.80

Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci (2014) 0.80

Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. J Crohns Colitis (2010) 0.79

New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics (2013) 0.79

Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine? Intern Med J (2016) 0.79

Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther (2008) 0.78

Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. Eur J Clin Pharmacol (2013) 0.78

A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. J Crohns Colitis (2012) 0.78

Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 0.78

Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis (2013) 0.78

The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients. J Crohns Colitis (2013) 0.78

How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease? Scand J Gastroenterol (2011) 0.78

Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis (2015) 0.78

Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels. Ann Pharmacother (2014) 0.77

Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis. Inflamm Bowel Dis (2013) 0.77

Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease. Ther Drug Monit (2015) 0.77

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis (2013) 0.76

[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]. Gastroenterol Hepatol (2006) 0.76

Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern Med J (2013) 0.76

Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients. J Clin Pharmacol (2013) 0.76

Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience. J Crohns Colitis (2013) 0.75

Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms. World J Gastroenterol (2015) 0.75

Letter: metabolite monitoring for thiopurines in Crohn's disease - still not fully understood. Aliment Pharmacol Ther (2014) 0.75

Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C. Yonsei Med J (2013) 0.75

Is less more: does leukopenia predict remission in patients with inflammatory bowel disease receiving thiopurine treatment? Dig Dis Sci (2015) 0.75